This recurrence probability score combines the protein expression of triple receptors and Ki-67, along with a Clinical Treatment Score (age, tumor size, nodal status, tumor grade, and endocrine treatment: tamoxifen versus anastrozole) to stratify the residual disease risk into four categories: very low, low, intermediate and high [80,81]. The gene discussed is MKI67; the disease is neoplasm.